Immunotherapy最新文献_第5页

NKT cells-a generalist in disease treatment and a new key to unlock immunotherapy. NKT细胞——疾病治疗的通才，开启免疫治疗的新钥匙。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-29 DOI: 10.1080/1750743X.2025.2525739

Guanhua Lyu, Xu Wang, Xixi Li, Peiwen Li, Yurou Chen, Xinyao Zhang, Yuping Ren, Xunuo Sun, Xinmei Wang, Xiangyu Wang, Junyu Liu

{"title":"NKT cells-a generalist in disease treatment and a new key to unlock immunotherapy.","authors":"Guanhua Lyu, Xu Wang, Xixi Li, Peiwen Li, Yurou Chen, Xinyao Zhang, Yuping Ren, Xunuo Sun, Xinmei Wang, Xiangyu Wang, Junyu Liu","doi":"10.1080/1750743X.2025.2525739","DOIUrl":"10.1080/1750743X.2025.2525739","url":null,"abstract":"NKT cells (natural killer T cells) are a subpopulation of specialized T cells that recognize lipid antigens presented by CD1d molecules, which can be classified into type I NKT cells, type II NKT cells and NKT-like cells. NKT cells play a key role in linking innate and adaptive immunity. In recent years, NKT cells have been found to be involved in the development of various systemic diseases, including tumors, respiratory system diseases, autoimmune diseases, reproductive system diseases, gastrointestinal system diseases and liver diseases. Thus, immunotherapy targeting NKT cells has brought novel strategies for the treatment of cancers and other diseases. Currently, NKT cell-based immunotherapy includes NKT cell agonist, CAR-NKT and NKT gene editing. Among them, α-galactosylceramide (α-GalCer), a NKT cell agonist, has demonstrated promising applications in enhancing vaccine immunogenicity and anti-tumor immunity. In conclusion, this review systematically summarizes the development, differentiation, classification, and function of NKT cells, as well as their relationships with systemic diseases. Additionally, this review also emphasizes the prospects for the clinical application of NKT cell-based immunotherapy. Future research should focus on the development of novel NKT cell-targeted therapeutic strategies and vaccine adjuvants to advance personalized medicine and precision immunotherapy.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"667-683"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study. nivolumab治疗转移性肾细胞癌的尿酸水平：土耳其肿瘤组肾癌联盟（TKCC）的一项研究

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-07-03 DOI: 10.1080/1750743X.2025.2527019

Serhat Sekmek, Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, Saadet Sim, Hilal Karakaş, Murad Guliyev, Aysun Fatma Akkus, Selver Isık, Gökhan Uçar, Deniz Tural, Cagatay Arslan, Sema Sezin Goksu, Ozlem Nuray Sever, Nuri Karadurmus, Cengiz Karacin, Mehmet Ali Nahit Sendur, Emre Yekedüz, Yüksel Ürün

{"title":"Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study.","authors":"Serhat Sekmek, Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, Saadet Sim, Hilal Karakaş, Murad Guliyev, Aysun Fatma Akkus, Selver Isık, Gökhan Uçar, Deniz Tural, Cagatay Arslan, Sema Sezin Goksu, Ozlem Nuray Sever, Nuri Karadurmus, Cengiz Karacin, Mehmet Ali Nahit Sendur, Emre Yekedüz, Yüksel Ürün","doi":"10.1080/1750743X.2025.2527019","DOIUrl":"10.1080/1750743X.2025.2527019","url":null,"abstract":"Aims: To investigate the effect of uric acid level on prognosis in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab.Materials and methods: This retrospective study utilized data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC), which is a multicenter registry encompassing 13 cancer centers across Türkiye.Results and conclusions: A total of 189 patients were included in the study. The median age was 61 years in all cohort. Univariable analyses revealed longer TTF (17.87 vs. 6.57 months, p = 0.014) and OS (52.01 vs. 25.36, p = 0.032) in the uric acid-high (UAH) group than in the uric acid-low (UAL) group. In multivariable analyses, low uric acid level emerged as an independent risk factor for OS (hazard ratio (HR): 1.82, 95% confidence interval (CI): 1.09-3.05; p = 0.022), whereas no significant association was observed with TTF (HR: 1.24, 95% CI: 0.72-2.13; p = 0.431). While uric acid levels were a significant independent prognostic factor for OS, no association was found with TTF. Our findings underscore the prognostic importance of uric acid in mRCC, suggesting its potential role as a biomarker for risk stratification.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"649-655"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IgE-mediated anaphylaxis induced by pembrolizumab. 派姆单抗诱导ige介导的过敏反应。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-07-08 DOI: 10.1080/1750743X.2025.2527589

Romane Legroux, Jeanne-Marie Perotin, Gabrielle Wintrebert, Julien Ancel

{"title":"IgE-mediated anaphylaxis induced by pembrolizumab.","authors":"Romane Legroux, Jeanne-Marie Perotin, Gabrielle Wintrebert, Julien Ancel","doi":"10.1080/1750743X.2025.2527589","DOIUrl":"10.1080/1750743X.2025.2527589","url":null,"abstract":"The increasing use of biologics in cancer treatment is associated with an increase in drug-related hypersensitivity reactions (HSR) of varying severity. Pembrolizumab is a humanized monoclonal antibody specifically targeting the programmed cell death protein 1 (PD-1) receptor, largely used in lung cancer and other malignancies. Pembrolizumab-related HSR has rarely been described, with very few reported positive allergy tests.We describe the case of a 77-year-old man treated for metastatic lung adenocarcinoma, who presented a severe anaphylactic reaction during the 8th pembrolizumab administration. Allergy tests confirmed the type I IgE-mediated hypersensitivity mechanism.Based on the four published cases, immediate HSR induced by pembrolizumab can occur after several treatment courses with potentially severe anaphylactic reactions. Mild symptoms during the preceding courses might occur and should be monitored. Skin tests are reliable, safe, and useful to guide management. When immediate HSR induced by pembrolizumab is confirmed, rapid drug desensitization may be considered. Further studies are needed to identify risk factors for immediate HSR induced by pembrolizumab.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"625-629"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oncolytic immunovirotherapy: finding the tumor antigen needle in the antiviral haystack. 溶瘤免疫病毒治疗：在抗病毒药物的大海捞针中寻找肿瘤抗原。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-06 DOI: 10.1080/1750743X.2025.2513853

Benjamin L Kendall, Richard G Vile

{"title":"Oncolytic immunovirotherapy: finding the tumor antigen needle in the antiviral haystack.","authors":"Benjamin L Kendall, Richard G Vile","doi":"10.1080/1750743X.2025.2513853","DOIUrl":"10.1080/1750743X.2025.2513853","url":null,"abstract":"Immunovirotherapy integrates the oncolytic capabilities of viruses with the modulation of the host immune system to establish robust tumor-specific immune responses. Oncolytic viruses (OVs) are natural or engineered viruses that specifically replicate in and lyse tumor cells, triggering inflammation which recruits immune effector cells to the site of infection. These conditions theoretically synergize with immune checkpoint blockade (ICB), which aids in establishing and maintaining tumor-infiltrating CD8 T cells. However, clinical data directly confirming synergy between OV and ICB therapy is limited despite ICB becoming the standard of care for several cancer types. It has been shown that viral immunodominance may limit antitumor T-cell priming and cause the attrition of tumor-specific T cells, limiting long-term therapeutic efficacy. To overcome these barriers, precise incorporation of virally expressed or exogenously administered tumor-associated antigens (TAAs) can synchronize the expansion of both antiviral and antitumor T cells, creating optimal conditions for ICB treatment. This tripartite approach leverages our understanding of antiviral immunity to efficiently expand subdominant antitumor T cells in vivo. In this review, we dissect the fundamental paradigm of immunovirotherapy regarding antiviral inflammation and TAAs, followed by relevant combinatorial strategies employed in preclinical and clinical settings for the treatment of solid tumors.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"585-594"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic lymph node dissection with neoadjuvant immunotherapy for macroscopic melanoma - too much skin in the game? 治疗性淋巴结清扫与新辅助免疫治疗宏观黑色素瘤-太多的皮肤在游戏中？

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-07-01 DOI: 10.1080/1750743X.2025.2527574

Sze Wah Samuel Chan, Michael Au, Adi Kartolo

引用次数: 0

Chemotherapy-free treatment of B-lymphoid/myeloid mixed phenotype acute leukemia: two case reports and literature review. 无化疗治疗b淋巴/髓混合表型急性白血病2例报告并文献复习。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-07-13 DOI: 10.1080/1750743X.2025.2527018

Yi-Fan Wang, Jing-Ying Dai, Ming-Yong Li, Tao Jiang

{"title":"Chemotherapy-free treatment of B-lymphoid/myeloid mixed phenotype acute leukemia: two case reports and literature review.","authors":"Yi-Fan Wang, Jing-Ying Dai, Ming-Yong Li, Tao Jiang","doi":"10.1080/1750743X.2025.2527018","DOIUrl":"10.1080/1750743X.2025.2527018","url":null,"abstract":"B-lymphoid/myeloid mixed phenotype acute leukemia (MPAL) is a rare subtype of acute leukemia that most likely originates from hematopoietic pluripotent stem cells. It is a heterogeneous group of leukemia characterized by the expression of more than 1 specific marker from each hematopoietic lineage (lymphoid and myeloid-specific antigens). The MLL-AF4 fusion gene is a common genetic abnormality in MPAL. Due to the lack of thorough understanding and the rare occurrence of B-lymphoid/myeloid MPAL, it presents substantial challenges in determining the standard treatment protocol. The absence of a widely accepted optimal treatment for MPAL has indicated the need for a more effective and less toxic approach. This case report presents two cases of B-lymphoid/myeloid MPAL with MLL-AF4 genetic abnormality successfully treated with a chemo-free regimen composed of venetoclax, hypomethylating agents, and blinatumomab and achieved complete remission (CR). Considering the results of this case report, the combination of a chemotherapy-free regimen could be considered a safe and effective treatment approach for patients with B-lymphoid/myeloid MPAL.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"639-647"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biology-driven therapies of CAR T immune effector cell-associated neurotoxicity syndrome. CAR - T免疫效应细胞相关神经毒性综合征的生物学驱动疗法。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-01 Epub Date: 2025-05-29 DOI: 10.1080/1750743X.2025.2510893

Sophie Giesler, Francesca Biavasco, Tobias Wertheimer, Robert Zeiser, Janaki Manoja Vinnakota

引用次数: 0

Dietary impacts on prostate cancer immunotherapy. 饮食对前列腺癌免疫治疗的影响。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-01 Epub Date: 2025-05-29 DOI: 10.1080/1750743X.2025.2511472

Loan D Duong, Xin Lu

{"title":"Dietary impacts on prostate cancer immunotherapy.","authors":"Loan D Duong, Xin Lu","doi":"10.1080/1750743X.2025.2511472","DOIUrl":"10.1080/1750743X.2025.2511472","url":null,"abstract":"Prostate cancer is a leading cause of cancer-related mortality in men. While early-stage disease is readily treated, advanced-stage prostate cancer has a poor survival rate and limited effective therapies. Immunotherapy has achieved significant success in other malignancies, but prostate cancer is characterized by an immunosuppressive, \"cold\" tumor microenvironment that blunts immunotherapy efficacy. Emerging evidence suggests that dietary interventions - such as ketogenic diets, methionine restriction, and bioactive compounds like white button mushroom extract - can modulate the tumor microenvironment and enhance immunotherapy responses in preclinical and early clinical studies. Additionally, specific diet-derived factors (such as the ketone body β-hydroxybutyrate) have demonstrated anti-tumor immune effects on their own, representing new avenues for combination therapy. While prior reviews have addressed diet or immunotherapy in prostate cancer independently, this review integrates these domains with the aim of offering a streamlined perspective. This brief review synthesizes recent findings on dietary modulation of prostate cancer immunity, with a focus on mechanistic insights that may be leveraged to augment immunotherapy, to suggest potential combination strategies and inform future translational efforts.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"525-536"},"PeriodicalIF":2.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating remibrutinib in the treatment of chronic spontaneous urticaria. 评价瑞米鲁替尼治疗慢性自发性荨麻疹的疗效。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-01 Epub Date: 2025-06-02 DOI: 10.1080/1750743X.2025.2510892

Agnieszka Bożek, Adam Reich

{"title":"Evaluating remibrutinib in the treatment of chronic spontaneous urticaria.","authors":"Agnieszka Bożek, Adam Reich","doi":"10.1080/1750743X.2025.2510892","DOIUrl":"10.1080/1750743X.2025.2510892","url":null,"abstract":"Chronic spontaneous urticaria (CSU) is a complex inflammatory skin condition that significantly impacts patients' quality of life. Conventional treatments, such as antihistamines, often fail to provide adequate symptom control. The next step involves administering omalizumab, a monoclonal antibody targeting IgE, however, a subset of patients may not respond to this treatment underscoring the necessity for alternative treatment options. Remibrutinib, an oral, selective inhibitor of Bruton's tyrosine kinase (BTK), has emerged as a promising therapy in CSU. BTK is vital for the activation of mast cells and basophils. The inhibitory action of remibrutinib on BTK may help alleviate CSU symptoms by addressing mast cell-mediated inflammation. Clinical trials, including Phase II and III studies, have shown promising efficacy and a favorable safety profile for remibrutinib in treating CSU. Patients experienced rapid symptom relief, with notable improvements in the Urticaria Activity Score (UAS7) concerning both itch intensity and the severity of hives. The safety profile was also commendable, with no significant treatment-related adverse events requiring therapy cessation or posing immediate health risks to patients. These results indicate that remibrutinib may become a preferred oral treatment for patients with moderate to severe CSU who do not adequately respond to standard therapies.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"479-484"},"PeriodicalIF":2.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The complexities of PD-L1 expression as an indicator of immunotherapy outcomes. PD-L1表达的复杂性是免疫治疗结果的一个指标。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-01 Epub Date: 2025-05-05 DOI: 10.1080/1750743X.2025.2500908

Robert A Needleman, Alesha A Thai

引用次数: 0